J. Castillo

J. Castillo

Auto-generated profile, based on publicly available information

J. Castillo

INCLIVA Health Research Institute, Hospital Clinico Universitario de Valencia, avenida Menendez y Pelayo 4, 46010, Valencia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
VGV. Gambardella
V. Gambardella
ASA. Sampera
A. Sampera
JCJ. Castillo
J. Castillo
FSF. Sánchez-Martín
F. Sánchez-Martín
FGF. Gimeno-Valiente
F. Gimeno-Valiente
Andres CervantesAndres Cervantes
Andres Cervantes
Background: HER2 receptor amplification or overexpression represents an important driver in 7-34% of cases of GC, playing a relevant role in cell growth, survival and differentiation. In HER2 positive GC, trastuzumab, a humanized antibody against HER2, when combined with 5FU/capecitabine and cisplatin, improves median overall survival. Nevertheless, primary and acquired resistance to the treatment eventually develops.